SCHEMBL24933738

SCHEMBL24933738

CC(C)S(=O)(=O)N1CCOC(COc2ccc(-c3cc(C(N)=O)c(=O)[nH]c3C(F)(F)F)cc2)C1

nearest known ligand 0.38

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ACLY P53396 1/20 0.38
IRAK4 Q9NWZ3 4/20 0.37
HRH3 Q9Y5N1 2/20 0.36
P2RX3 P56373 9/20 0.34
P2RX2 Q9UBL9 9/20 0.34
ALOX5AP P20292 2/20 0.34
FEN1 P39748 2/20 0.34
EPHX2 P34913 1/20 0.34
PRKAB2 O43741 1/20 0.33
PRKAG1 P54619 1/20 0.33
PRKAA2 P54646 1/20 0.33
PRKAA1 Q13131 1/20 0.33
PRKAG3 Q9UGI9 1/20 0.33
PRKAG2 Q9UGJ0 1/20 0.33
PRKAB1 Q9Y478 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29203334 0.96 LMNA (0.36) ACLYIRAK4HRH3P2RX3P2RX2
SCHEMBL24933817 0.87 IRAK4 (0.34) ACLYIRAK4HRH3P2RX3P2RX2
SCHEMBL24933739 0.85 IRAK4 (0.36) IRAK4HRH3P2RX3P2RX2EPHX2
SCHEMBL24933835 0.85 PDK1 (0.40) IRAK4EPHX2PRKAB2PRKAG1PRKAA2
SCHEMBL24933560 0.84 P2RX3 (0.41) HRH3P2RX3P2RX2
SCHEMBL24932963 0.83 PDK1 (0.34) IRAK4HRH3EPHX2PRKAB2PRKAG1
SCHEMBL24933840 0.83 PRKAB2 (0.46) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL24933831 0.82 P2RX3 (0.42) P2RX3P2RX2
SCHEMBL24932993 0.82 DRD4 (0.39) HRH3
SCHEMBL24933681 0.82 DRD4 (0.39) HRH3PRKAB2PRKAG1PRKAA2PRKAA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373809-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS Novartis AG (CH) 2024-05-29 EP claimed
CN-117980292-A Substituted pyridone compounds for the treatment of orthomyxoviral infections 诺华股份有限公司 2024-05-03 CN claimed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO claimed
EP-4373809-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS Novartis AG (CH) 2024-05-29 EP disclosed
CN-117980292-A Substituted pyridone compounds for the treatment of orthomyxoviral infections 诺华股份有限公司 2024-05-03 CN disclosed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO disclosed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO disclosed